Sun Pharma slips nearly 4% amid reports of $12 bn Organon deal

Shares of Sun Pharmaceutical Industries fell nearly 4% on Friday after reports suggested the company is moving ahead with a binding $12-billion offer for US-based Organon. As per BSE data, Sun Pharma was trading at ₹1,650.70, down by ₹66.65 or 3.88%, around 2 pm. Sun Pharma is reportedly into financial arrangements with global banks, including JPMorgan and MUFG.